EGFR and ovarian cancer: Despite the existence of anti-EGFR-resistance in ovarian cancer cetuximab might exert immune modulating effects via antibody-dependent cellular cytotoxicity (ADCC) and might enhance antitumoural activity in a NK cell-based immunotherapeutic approach.